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[Manuscript comprises 4211 words]
Abstract
Background
Depressed individuals often do not respond to medication or psychotherapy. Radically Open 
Dialectical Behaviour Therapy (RO DBT) is a new treatment targeting overcontrolled personality, 
common in refractory depression.
Aim
To compare RO DBT plus treatment as usual (TAU) for refractory depression with TAU alone.
Methods
RO DBT comprised 29 therapy sessions and 27 skills classes over six months. Our completed 
randomised trial evaluated RO DBT for refractory depression over 18 months in 3 British secondary 
care centres. Of 250 adult participants, we randomised 162 (65%) to RO DBT. The primary outcome 
was the Hamilton Rating Scale for Depression (HRSD), assessed blind and analysed by treatment 
allocated. 
Results
After seven months, immediately following therapy, RO DBT had reduced depressive symptoms by 
5.40 HRSD points relative to TAU [95% confidence interval (CI) +0.94 to +9.85]. After 12 months 
(primary end point), the difference of 2.15 HRSD points in favour of RO DBT was not significant (95% 
CI –2.28 to +6.59); nor was that of 1.69 HRSD points at 18 months (95% CI –2.84 to +6.22). 
Throughout RO DBT participants reported significantly better psychological flexibility and emotional 
coping than controls. However they reported eight possible Serious Adverse Reactions (SARs) 
compared with none by controls.
Conclusions 
RO DBT participants reported significantly lower HRSD scores than controls after 7 months, but not 
thereafter. The imbalance in SARs was probably due to controls’ limited opportunities to report 
these.  
Declaration of interest
Six of the 16 authors have received royalties or fees for RO DBT. 
[Abstract comprises 249 words cf limit of 250] 
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Introduction
Major depressive disorder is a recurrent, disabling condition causing substantial impairment in 
psychosocial functioning and quality of life.1 Only one third of individuals respond fully to 
antidepressant medication (ADM) and only half to psychological treatment.2  Recently treatments 
developed for refractory depression have achieved small to moderate effect sizes.3 Treatments are 
seldom effective owing to co-morbidity, especially personality disorders (PD).4 About half of unipolar 
depressed patients meet criteria for comorbid PD, with higher rates among those with chronic or 
treatment-resistant depression.4,5 The commonest PDs among depressed individuals show excessive 
inhibitory control or overcontrol, including Cluster A (paranoid PD) and Cluster C (obsessive-
compulsive and avoidant PD) — those that respond poorly to PD treatments.6,7 The core 
characteristics of overcontrolled personality disorders are: cognitive and behavioural rigidity; strong 
desire to control one’s environment; restrained emotional expression; limited social interaction; and 
problems with close relationships due to aloofness, distancing, mistrust and fear of rejection or 
criticism.8 Radically Open Dialectical Behaviour Therapy (RO DBT), a novel trans-diagnostic 
psychotherapy, aims to address this rigid coping style.9 Earlier versions of RO DBT showed promise in 
two pilot randomised trials of patients with refractory depression and comorbid PD.10,11 This trial 
aimed to assess the efficacy of RO DBT for refractory depression,12 and whether RO DBT causes 
identifiable harms.13
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Methods
Design 
RefraMED was a three-centre parallel-group randomised trial which compared RO DBT plus 
treatment as usual (TAU) with TAU alone. After an internal pilot in one centre, shortage of therapists 
reduced recruitment below the target rate. So we extended our recruitment period from 24 months 
to 32; and followed the last 27 participants for 12 months (the primary endpoint) rather than 18. 
Participants
Patients were eligible for the RefraMED trial if they: were 18 years or older; had an IQ more than 70; 
spoke English well enough to participate; had a current diagnosis of major depressive disorder in 
SCID-I;14 were suffering from refractory depression, defined as chronic depression lasting at least 
two years or recurrent depression with at least two previous episodes; had a Hamilton Rating Scale 
for Depression (HRSD)15  score of at least 15; and had not responded to an adequate dose of ADM 
for at least six weeks in their current episode. Since we had developed RO DBT specifically for 
overcontrol, we excluded patients who: met criteria for bipolar disorder, psychosis, or dramatic-
erratic PD in SCID-II;16 had a primary diagnosis of substance dependence; or were currently receiving 
or waiting for standard DBT. We recruited these patients in three NHS secondary care centres 
already delivering standard DBT for dramatic-erratic PD – Dorset and Hampshire in England, and 
North Wales.13
Interventions
Treatment as usual (TAU)
As all three centres seek to deliver best practice, that was the natural control treatment. All 
participants received TAU, including prescribed ADM or psychotherapy. 13 Control participants could 
also access any treatment from NHS or privately, except standard DBT. At each follow-up assessors 
asked participants to report their ADM and adherence to it, and psychotherapy accessed since their 
previous assessment or in the six months before their baseline assessment. 
Radically Open Dialectical Behaviour Therapy (RO DBT)
RO DBT is a trans-diagnostic therapy designed to address a spectrum of disorders that are difficult to 
treat, notably chronic depression.9 It differs from other psychotherapies, notably by encouraging 
social bonding through emotional expression. At the time of the trial RO DBT comprised 29 weekly 
individual therapy sessions each lasting an hour and 27 skills training classes each lasting 2.5 hours. 
9,12 The RO DBT lesson plan (Table S1) included new RO DBT lessons9 and standard DBT lessons.17 RO DBT 
began soon after participants learned their treatment allocation. Though they continued to receive 
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ADM as prescribed, we strongly discouraged them from seeking additional psychotherapy during RO 
DBT. 
The RO DBT developer (TRL) did not contribute to treatment delivery. He led the ten-day programme 
to train the 23 recruited therapists – eight in Dorset, ten in Hampshire and five in North Wales; and 
supervised them thereafter. Two were male, and ages ranged from 32 to 61 years. All therapists 
were standard-DBT therapists with a minimum of 3 years clinical experience. To be recruited, 
therapists had to submit three treatment tapes rated as adherent on the standard DBT Adherence 
Coding Scale – the recognised measure of adherence in standard DBT,18 relevant also to RO DBT. All 
therapists attended weekly team meetings, to enhance treatment adherence and reduce therapist 
burnout. We maintained treatment fidelity across the trial by applying the standard DBT scale18 to 
randomly sampled sessions; and feeding scores back to therapists and their site leaders.
Outcome measures13 
Primary outcome
The primary outcome was the severity of depressive symptoms 12 months after randomisation, that 
is five months after the end of treatment. Trained assessors measured this by the 17-item Hamilton 
Rating Scale for Depression (HRSD).15 Participants completed the HRSD at four points – baseline, and 
seven (immediately after treatment), 12 and 18 months after randomisation. We chose seven 
months rather than six, when most clients were still attending treatment sessions, to make 
RefraMED more comparable with other trials that assess response to treatment immediately after 
that treatment. We judged it most useful to evaluate RO DBT after a full year, when remission is 
most important, even though psychotherapies are usually evaluated immediately after the end of 
therapy. 
Secondary outcomes
We assessed remission from HRSD scores and psychosocial functioning measured by the 
Longitudinal Interval Follow-up Evaluation – Range of Impaired Functioning Tool (LIFE-RIFT):19 We 
defined full remission as HRSD score below 8 and LIFE-RIFT score below 13; and partial remission as 
HRSD score below 15 and LIFE-RIFT score below 13 points.
We measured suicidal ideation using the assessor-rated Modified Scale for Suicidal Ideation (MSSI);20 
total scores less than 9 show low ideation. 
After three months, and the other four points, we collected data on potential mediating variables:
Acceptance & Action Questionnaire-II (AAQ-II)21 measuring psychological inflexibility. 
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Emotional Approach Coping (EAC) scale22 measuring Emotional Processing and Emotional 
Expression. 
Patient Health Questionnaire-9 (PHQ-9)23 measuring depression severity.
The 3-item Social Support Questionnaire (SSQ-3)24 measuring responders’ satisfaction with support.
At baseline we also recorded potential moderating variables, notably age, sex and marital status. 
Sample size 
Two pilot studies of an earlier but similar version of RO DBT for refractory depression showed effect 
sizes at end of treatment of 0.8511 and 0.71.10  We aimed to recruit enough analysable participants to 
yield 80% power to detect as statistically significant at the 5% level a standardised difference of 0.4 
between RO DBT and TAU. We judged that clinicians and the UK National Institute of Health and 
Care Excellence (NICE) would consider this, equivalent to a mean difference of two points on the 
HRSD, to be ‘clinically important’. 
If there were no correlation between patients with the same therapist, a sample of 200 analysable 
participants would detect such a difference. As we aimed to collect analysable data from at least 
83% of participants, we increased our target to 240. To focus on the mechanisms of RO DBT we 
randomised in the ratio 3:2 by allocating 144 ‘unclustered’ patients to RO DBT and 96 to TAU. 
However RO DBT participants cluster by therapist. To allow for an intra-therapist correlation 
coefficient of 0.025 between HRSD scores, and an average cluster size of 11 participants for each of 
the expected 16 therapists, we increased the RO DBT sample size to 180, yielding the same statistical 
power as 144 unclustered participants. Thus we aimed to randomise 276 patients – 180 to RO DBT 
and 96 to TAU. We planned no interim analysis or stopping rule apart from that imposed by funding.
Randomisation and masking
Once we had confirmed eligibility and received informed consent through the form approved by 
Hampshire Research Ethics Committee, we randomised participants between treatments. We used 
three stratifying variables to ensure balance between groups – early or late onset of depression, 
HRSD score above or below 25, and presence or absence of PD. Within the RO DBT group, we 
randomised participants between available therapists so as to use as many as feasible of the 
treatment slots at each centre. To minimise risk of subversion, the Swansea Trials Unit used dynamic 
randomisation to make these allocations stochastically rather than deterministically.25 They emailed 
the resulting allocations to the Trial Manager for dissemination to participants and study therapists, 
but not assessors.
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To keep assessors blind to treatment allocations they: conducted assessments away from treatment 
centres; asked participants not to reveal their allocations during assessments; and avoided clinical 
notes after initial assessment. If an allocation were revealed, we reblinded by using another assessor 
for later assessments. If the allocation were revealed during assessment, we used the unblinded 
ratings; this happened 17 times at month seven, 12 times at month 12, but not at all at month 18. 
Assessor Reliability13
A clinical psychologist experienced in administering SCID and HSRD in clinical trials (HO’M) trained 
assessors to administer all these outcome measures. The minimum requirement for RefraMED 
assessors was a degree in Psychology or closely related field. In reality all assessors had 
postgraduate qualifications, mainly MSc, DClinPsy or PhD. We discussed queries at weekly consensus 
meetings. We assessed inter-rater reliability for the HRSD at 9-month intervals across nine assessors. 
We analysed the reliability of individual items, more rigorous than analysing total scores. Across all 
measurements Krippendorff’s alpha was 0.89 (95% CI from 0.86 to 0.92), implying “very good” to 
“near perfect” inter-rater reliability.26
Statistical methods
To create a dataset for analysis, we linked study datasets by randomisation codes. We validated this 
database by comparing information across sources, and by entering data twice. We scored all 
measures according to their published rules for imputing missing data. 
We used the lmerTest package for the statistical language R to fit linear mixed effects models to 
primary and secondary outcomes over the 18 months from baseline.27 Covariates included 
treatment allocated, treatment centre, baseline HRSD score, early or late onset of depression, and 
presence or absence of PD at baseline. We used a 3-level mixed-effects model to account for 
clustering of data by patient and therapist, avoiding the assumption that all therapists are equally 
effective. These mixed models are efficient and unbiased when data are missing at random. Without 
suitable auxiliary data we did not impute missing responses, for example by multiple imputation. 
However, when fewer than 10% of items were missing in a given scale, we imputed them by linear 
regression using the other scale items as covariates. For each outcome we estimated the main 
effects of treatment allocation and time, and the interaction between them; and compared groups 
at months 7, 12 and 18 by treatment allocated. 
In assessing remission from depression, we used Button’s criterion of 17.5% change in HRSD scores 
from baseline.28 We refitted our mixed models using the Bayesian software Stan, and the associated 
R package ‘brms’.29 We assessed heterogeneity in therapist performance by intra-therapist 
correlation coefficients (ICCs), and simulated prognoses for future patients on RO DBT. Analyses post 
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hoc estimated posterior odds ratios30 for hypotheses of interest. We derived remission rates from 
predictions based on continuous outcomes, so did not need to test for differences in these rates 
directly. 
Serious adverse events
Our report to NIHR describes how we monitored Serious Adverse Events (SAEs).13 The Chief 
Investigator reviewed these immediately, and reported them to the Data Monitoring & Ethics 
Committee (DMEC) every year, or immediately if there was Suspicion of an Unexpected Serious 
Adverse Reaction (SUSAR). 
Ethical approval and conduct
Before recruiting patients we gained approval from the Hampshire Research Ethics Committee 
(National Research Ethics Service [NRES] reference 11/SC/0146) and the Research Governance 
Department of the University of Southampton, the Sponsor of this trial. We asked trial participants 
for consent on three occasions: before telephone screening; before baseline assessment; and before 
randomisation.
Patient and public inclusion
The NIHR Mental Health Research Network and ‘Involve’, the national advisory group on public 
engagement, helped us recruit service users – two to the Trial Steering Committee (TSC) and two to 
the Trial Management Group (TMG). These users contributed to patient information leaflets, 
managing the trial, and disseminating findings.
Data availability 
All non-confidential data and syntax for analyses reported here are available in the online data 
supplement with doi: 10.5281/zenodo.1442883. 
Role of the funding source
The Efficacy & Mechanism Evaluation (EME) Programme, funded by the MRC and administered by 
the National Institute for Health Research (NIHR), funded this trial by grant 09/150/12. NIHR 
monitored the trial and appointed the independent members of the TSC and DMEC. The grant 
holders were responsible for: study design; collecting, analysing, and interpreting data; writing this 
paper; and submitting for publication.
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Results
 Insert Figure 1 here
Recruitment
Figure 1 shows the flow of participants through the RefraMED trial: we randomised 250 eligible 
patients, 162 (65%) to RO DBT and 88 to control. Recruitment started in Dorset in March 2012 with an 
internal pilot; started in Hampshire and North Wales in September 2012; and continued until April 
2015. Of the 250 randomised participants, 170 (68%) came from secondary care, 55 (22%) from 
primary care database searches, 19 (8%) from self-referral and six (2%) from other sources, notably 
private practitioners.13 
Of 162 participants allocated to RO DBT plus TAU, 34 (21%) withdrew, including ten who attended no 
sessions, four who attended only one or two sessions; and ten prevented from continuing by work or 
family commitments. If participants did not attend a follow-up appointment after 7 or 12 months, we 
asked them to attend the next scheduled follow-up. For example, six of the fourteen RO DBT 
participants who did not attend their appointment after 7 months did attend their appointment after 
12 months. This explains why we analysed more participants after 12 months (130) than after 7 (124).
Of 88 control participants, 22 (25%) withdrew, including nine because they resented allocation to 
TAU. Only one of those withdrawing from treatment agreed to stay in the study for follow-up 
interviews. So the proportion of participants analysed at month 12 did not differ significantly between 
groups (Chi squared = 0.71 with one degree of freedom; p = 0.40).  
Baseline data – demographic and clinical
Of the full sample of 250, 164 (64%) were female; 138 (55%) were aged between 35 and 55; 232 (97% 
of 238 responders) were ‘white’; 106 (42%) reported being in a stable relationship; and 82 (34% of 
241 responders) had a University qualification. Ninety-two participants (37%) reported a first 
depressive episode before the age of 16; 179 (84% of 213 responders) were chronically rather than 
recurrently depressed; and 191 (82% of 234 responders) had previously received psychotherapy. Our 
sample also showed high comorbidity: 217 (87%) with at least one axis-I disorder, and 197 (79%) with 
at least one axis-II disorder; only nine (4%) had no psychiatric comorbidity.13 Our report also confirms 
that our adaptive randomisation procedure was effective in balancing the characteristics of 
participants across groups; treatment centres were also generally comparable in participants’ 
characteristics.13
Delivery of therapy
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Of 23 therapists we trained, one did not provide therapy within RefraMED. The number of 
participants seen by the other therapists ranged from one to 17, with a mean of 6.9 and median of 7. 
The mean number of individual sessions attended by participants was 22.9 (SD 6.9; 79% of the 29 
planned); while the mean number of group sessions attended was 19.9 (SD 7.6; 74% of the 27 
planned).
Treatment fidelity
We rated 273 (9%) tapes; and adjudged 221 (81%) of these adherent with a score of 4.0 or more. 
Primary outcome: depressive symptoms measured by HRSD
Table 1 and Figure 2 compare HRSD and the five secondary continuous outcome variables between 
groups across all follow-ups. 
 INSERT Table 1 and Figure 2
Depressive symptoms in both groups improv d continuously from baseline to 18 months. By the end 
of therapy at seven months, RO DBT had substantially reduced depressive symptoms relative to TAU 
by 5.40 HRSD points (95% CI 0.94 to 9.85; effect size = 1.03; p = 0.02). RO DBT participants maintained 
their improvement in depressive symptoms at 12 and 18 months, but control participants improved 
more after 7 months, reducing the difference between-groups. The difference of 2.15 HRSD points at 
12 months exceeded our prior target of 2 points but was not statistically significant (95% CI -2.28 to 
6.58; effect size = 0.41; p = 0.29). At 18 months the difference fell to 1.69 HRSD points (95% CI -2.84 to 
6.22; effect size = 0.32; p = 0.42). Thus our planned contrasts revealed a statistically significant 
difference between RO DBT and TAU after seven months, but not after 12 or 18 months. In contrast 
Bayesian analysis post hoc provided evidence that RO DBT was superior to TAU across all follow-ups: 
the posterior odds ratio was: 46 at 7 months – suggesting “strong” evidence;30 and 5.5 and 4.7 at 12 
and 18 months respectively – suggesting “positive” evidence.30  Figure 3 displays the posterior 
probability that RO DBT achieved the range of effects on the x-axis. The likely causes of the trial’s 
reduced power was the combination of under-recruitment and unexpectedly large therapist 
heterogeneity, yielding an ICC of 0.14, much larger than the ICC of 0.025 postulated in our power 
analysis. The most and least effective therapists, judged by clinical outcomes of their participants, 
differed by 2.6 HRSD points, equivalent to a standardised effect size of 0.43.
 INSERT Figure 3
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Remission rates
Using primary criteria, full remission rates were low in both groups: 1%, 8% and 7% for RO DBT and 
0%, 0% and 1% in controls, at 7, 12 and 18 months respectively; and partial remission rates were 
higher for RO DBT – 23%, 26% and 33% at successive assessments – than in controls – 6%, 22% and 
24% at successive assessments. Using the criterion of ‘worthwhile’ change, namely 17.5% reduction in 
symptoms from baseline,28 remission rates were: 59%, 69% and 59% for RO DBT at 7, 12 and 18 
months; and 27%, 48% and 41% in controls. 
To help patients and clinicians interpret our findings, we simulated likely outcomes for new patients, 
estimating that, for every 100 new patients, 32 would achieve 17.5% improvement in symptom scores 
after 12 months by choosing RO DBT rather than TAU, while ten would deteriorate by the same 
criterion, and 58 would remain essentially unchanged.
Secondary continuous outcomes 
RO DBT participants achieved significant gains in psychological flexibility and emotional coping relative 
to controls throughout the trial (Table 1 and Figure 2). Mean AAQ scores, measuring psychological 
inflexibility decreased over time, especially after RO DBT; the effect size increased from 0.49 (medium) 
after seven months to 0.72 (large) after 12, and 0.79 after 18. EAC scores, measuring emotional 
coping, increased after RO DBT, but not after TAU; the ffect size increased from 0.32 (small) after 
seven months to 0.76 (large) after 12 months and 0.64 (also large) after 18. 
However Table 1 shows no significant advantage for RO DBT in suicidal ideation or perceived social 
support. Mean MSSI suicidal ideation scores remained low throughout the trial for both groups; and 
although mean SSQ (perceived social support) scores increased after RO DBT, the difference between 
groups was never significant. 
Serious adverse events
We received reports of 32 serious adverse events (SAEs) – four from the 88 participants allocated to 
TAU and 28 from the 162 participants allocated to RO DBT;13 none of these led to withdrawal from the 
trial. In the RO DBT group, 21 participants experienced a single event; two experienced two events 
each; and one participant experienced three events. Thus 24 RO DBT participants experienced SAEs. 
We judged that all four events in the TAU group and 13 in the RO DBT group were “definitely not 
related” to the study intervention, for example a leg fracture and one death due to natural causes. We 
judged that another eight were “unlikely to be related”, for example recurrent non-suicidal self-injury 
starting before the trial. Of the remaining eight SAEs, all from the intervention group, we judged that 
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five were “possibly related” to RO DBT, including two overdoses, and three were “probably related”, 
including a prevented suicide attempt. Nevertheless we classed none of those eight serious adverse 
reactions (SARs) as “suspected unexpected” requiring immediate reporting to the Research Ethics 
Committee.
Thus all eight serious adverse reactions judged as potentially related to RO DBT occurred in the 
intervention group (Fisher’s Exact Test; one-tailed p = 0.004). However trial assessors saw control 
participants only at the three follow-up interviews, so that SAE reporting relied on their volunteering 
relevant information. In contrast trial therapists saw RO DBT participants twice a week, and they 
completed diary cards reporting on suicidal ideation and self-harm. We tried to ameliorate reporting 
bias by asking participants’ GPs to report any SAEs they encountered. However no one outside the 
RefraMED team reported an SAE: control participants reported all four SAEs either during assessment 
or to the trial office. In the RO DBT group therapists reported 23 (82%) SAEs, and participants reported 
only five. We believe the imbalance was due to these gross differences in reporting opportunities and 
encouragement from therapists to use those opportunities. 
As in both previous trials of RO DBT,10,11 there were no suicides in this trial. For all these reasons the 
Data Monitoring Committee saw “no reason to suspect RO DBT had adverse effects on patients”.
Discussion
Principal findings
In participants with refractory depression, Radically Open Dialectical Behaviour Therapy (RO DBT) was 
not statistically superior to treatment as usual (TAU) on the Hamilton Rating Scale for Depression 
(HRSD) at our primary endpoint of 12 months after randomisation, despite achieving the target 
moderate effect size of 0.40. However it was substantially better than TAU immediately after 
treatment, with an effect size of 1.03, much larger than reported by previous trials of psychotherapy 
for refractory depression.4. The later fall in effect size stems from rapid improvement during RO DBT, 
and initially-slow but accelerating improvement during TAU. Bayesian analysis post hoc generated 
“positive” evidence of the superiority of RO DBT over 18 months; and suggests that 22% (viz 32% less 
10%) more patients would experience “worthwhile change” at 12 months by choosing RO DBT over 
TAU. 
Psychological outcomes
RO DBT aims to help individuals with rigid psychological and interpersonal styles learn flexibility. 
Reassuringly RO DBT participants reported significantly better psychological flexibility than the 
controls throughout the 18 months of follow up. RO DBT also aims to encourage appropriate 
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expression of emotion to avoid isolation. Again RO DBT participants reported significantly better 
emotional processing throughout these 18 months. Both findings suggest that participants continue to 
use and improve their RO DBT skills. However there was no significant advantage for RO DBT in 
suicidal ideation or perceived social support. Throughout the trial suicidal ideation was low in both 
groups; though this decreased further over time in both groups, the difference was never significant. 
This finding was probably due to both groups continuing to receive treatment and support either from 
the trial or from the National Health Service. Though social support scores increased after RO DBT and 
decreased after TAU, the difference between groups was never significant. 
Strengths
RO DBT is the first treatment known to us to target deficits in social signalling as the main problem 
underlying overcontrolled emotional loneliness. We designed RefraMED as a hybrid between a Phase 
2 efficacy trial and a Phase 3 effectiveness trial. The former yielded strengths in: the consistency of 
both intervention and assessment; allocating therapists to patients at random rather than allocating 
difficult patients to the most skilled therapists.13 The latter yielded strengths in: minimising exclusion 
criteria thus including a wide range of patients with depression and maximising generalisability; 
enabling the treatment developer to train therapists rather than provide therapy; and facilitating cost-
effectiveness analysis. 13 
Limitations
Despite our best efforts to recruit 276 participants, and analyse 229 (83%) of them, we recruited only 
250 and analysed only 190 (76%); we also encountered unexpectedly large therapist heterogeneity. 
Despite achieving our target effect size at 12 months, the resulting loss of power meant our pre-
planned analyses did not achieve statistical significance beyond month 7. 
Interpretation
RefraMED was the first multi-centre trial of RO DBT. Though RO DBT greatly improved depressive 
symptoms by the end of treatment, our planned analyses were not statistically significant thereafter. 
Bayesian analysis post hoc suggests that RO DBT was superior to TAU throughout, but this effect was 
not clinically significant after month 7.
RO DBT does not label depression as the primary problem. Instead it targets emotional overcontrol – a 
maladaptive personality style known to predict the development of chronic internalising disorders like 
refractory depression. Overcontrolled PDs, including obsessive-compulsive PD, are more common 
than undercontrolled PDs; and patients’ innate capacity to tolerate distress, delay gratification, and 
avoid public displays of emotion make their problems less noticeable, and them less likely to seek 
mental health treatment. Hence it is reassuring that RO DBT improved psychological flexibility and 
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emotional processing over 18 months in a highly symptomatic population, most of whom suffer 
several mental health problems. 
Implications for future research
Given the recurring nature of depression, and RO DBT’s aim of changing maladaptive personality, 
future studies should investigate long-term differences between RO DBT and other treatments. The 
high proportion of comorbid disorders in RefraMED (96%), and the evidence that patients with 
complex mental disorders do not benefit much from short-term psychotherapy,31 support this 
proposal. RO DBT’s trans-diagnostic approach justifies testing RO DBT across a range of conditions, 
including overcontrolled personality disorders (Clusters A and C), anxiety disorders, and eating 
disorders.32
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Abstract
Background
Depressed individuals often do not respond to medication or psychotherapy. Radically Open 
Dialectical Behaviour Therapy (RO DBT) is a new treatment targeting overcontrolled personality, 
common in refractory depression.
Aim
To compare RO DBT plus treatment as usual (TAU) for refractory depression with TAU alone.
Methods
RO DBT comprised 29 therapy sessions and 27 skills classes over six months. Our completed 
randomised trial evaluated RO DBT for refractory depression over 18 months in 3 British secondary 
care centres. Of 250 adult participants, we randomised 162 (65%) to RO DBT. The primary outcome 
was the Hamilton Rating Scale for Depression (HRSD), assessed blind and analysed by treatment 
allocated. 
Results
After seven months, immediately following therapy, RO DBT had reduced depressive symptoms by 
5.40 HRSD points relative to TAU [95% confidence interval (CI) +0.94 to +9.85]. After 12 months 
(primary end point), the difference of 2.15 HRSD points in favour of RO DBT was not significant (95% 
CI –2.28 to +6.59); nor was that of 1.69 HRSD points at 18 months (95% CI –2.84 to +6.22). 
Throughout RO DBT participants reported significantly better psychological flexibility and emotional 
coping than controls. However they reported eight possible Serious Adverse Reactions (SARs) 
compared with none by controls.
Conclusions 
RO DBT participants reported significantly lower HRSD scores than controls after 7 months, but not 
thereafter. The imbalance in SARs was probably due to controls’ limited opportunities to report 
these.  
Declaration of interest
Six of the 16 authors have received royalties or fees for RO DBT. 
[Abstract comprises 249 words cf limit of 250] 
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Introduction
Major depressive disorder is a recurrent, disabling condition causing substantial impairment in 
psychosocial functioning and quality of life.1 Only one third of individuals respond fully to 
antidepressant medication (ADM) and only half to psychological treatment.2  Recently treatments 
developed for refractory depression have achieved small to moderate effect sizes.3 Treatments are 
seldom effective owing to co-morbidity, especially personality disorders (PD).4 About half of unipolar 
depressed patients meet criteria for comorbid PD, with higher rates among those with chronic or 
treatment-resistant depression.4,5 The commonest PDs among depressed individuals show excessive 
inhibitory control or overcontrol, including Cluster A (paranoid PD) and Cluster C (obsessive-
compulsive and avoidant PD) — those that respond poorly to PD treatments.6,7 The core 
characteristics of overcontrolled personality disorders are: cognitive and behavioural rigidity; strong 
desire to control one’s environment; restrained emotional expression; limited social interaction; and 
problems with close relationships due to aloofness, distancing, mistrust and fear of rejection or 
criticism.8 Radically Open Dialectical Behaviour Therapy (RO DBT), a novel trans-diagnostic 
psychotherapy, aims to address this rigid coping style.9 Earlier versions of RO DBT showed promise in 
two pilot randomised trials of patients with refractory depression and comorbid PD.10,11 This trial 
aimed to assess the efficacy of RO DBT for refractory depression,12 and whether RO DBT causes 
identifiable harms.13
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Methods
Design 
RefraMED was a three-centre parallel-group randomised trial which compared RO DBT plus 
treatment as usual (TAU) with TAU alone. After an internal pilot in one centre, shortage of therapists 
reduced recruitment below the target rate. So we extended our recruitment period from 24 months 
to 32; and followed the last 27 participants for 12 months (the primary endpoint) rather than 18. 
Participants
Patients were eligible for the RefraMED trial if they: were 18 years or older; had an IQ more than 70; 
spoke English well enough to participate; had a current diagnosis of major depressive disorder in 
SCID-I;14 were suffering from refractory depression, defined as chronic depression lasting at least 
two years or recurrent depression with at least two previous episodes; had a Hamilton Rating Scale 
for Depression (HRSD)15  score of at least 15; and had not responded to an adequate dose of ADM 
for at least six weeks in their current episode. Since we had developed RO DBT specifically for 
overcontrol, we excluded patients who: met criteria for bipolar disorder, psychosis, or dramatic-
erratic PD in SCID-II;16 had a primary diagnosis of substance dependence; or were currently receiving 
or waiting for standard DBT. We recruited these patients in three NHS secondary care centres 
already delivering standard DBT for dramatic-erratic PD – Dorset and Hampshire in England, and 
North Wales.13
Interventions
Treatment as usual (TAU)
As all three centres seek to deliver best practice, that was the natural control treatment. All 
participants received TAU, including prescribed ADM or psychotherapy. 13 Control participants could 
also access any treatment from NHS or privately, except standard DBT. At each follow-up assessors 
asked participants to report their ADM and adherence to it, and psychotherapy accessed since their 
previous assessment or in the six months before their baseline assessment. 
Radically Open Dialectical Behaviour Therapy (RO DBT)
RO DBT is a trans-diagnostic therapy designed to address a spectrum of disorders that are difficult to 
treat, notably chronic depression.9 It differs from other psychotherapies, notably by encouraging 
social bonding through emotional expression. At the time of the trial RO DBT comprised 29 weekly 
individual therapy sessions each lasting an hour and 27 skills training classes each lasting 2.5 hours. 
9,12 The RO DBT lesson plan (Table S1) included new RO DBT lessons9 and standard DBT lessons.17 RO DBT 
began soon after participants learned their treatment allocation. Though they continued to receive 
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ADM as prescribed, we strongly discouraged them from seeking additional psychotherapy during RO 
DBT. 
The RO DBT developer (TRL) did not contribute to treatment delivery. He led the ten-day programme 
to train the 23 recruited therapists – eight in Dorset, ten in Hampshire and five in North Wales; and 
supervised them thereafter. Two were male, and ages ranged from 32 to 61 years. All therapists 
were standard-DBT therapists with a minimum of 3 years clinical experience. To be recruited, 
therapists had to submit three treatment tapes rated as adherent on the standard DBT Adherence 
Coding Scale – the recognised measure of adherence in standard DBT,18 relevant also to RO DBT. All 
therapists attended weekly team meetings, to enhance treatment adherence and reduce therapist 
burnout. We maintained treatment fidelity across the trial by applying the standard DBT scale18 to 
randomly sampled sessions; and feeding scores back to therapists and their site leaders.
Outcome measures13 
Primary outcome
The primary outcome was the severity of depressive symptoms 12 months after randomisation, that 
is five months after the end of treatment. Trained assessors measured this by the 17-item Hamilton 
Rating Scale for Depression (HRSD).15 Though Participants completed the HRSD at four points – 
baseline, and seven (immediately after treatment), 12 and 18 months after randomisation. We 
chose seven months rather than six, when most clients were still attending treatment sessions, to 
make RefraMED more comparable with other trials that assess response to treatment immediately 
after that treatment. We judged it most useful to evaluate RO DBT after a full year, when remission 
is most important, even though psychotherapies are usually evaluated immediately after the end of 
therapy. 
Secondary outcomes
We assessed remission from HRSD scores and psychosocial functioning measured by the 
Longitudinal Interval Follow-up Evaluation – Range of Impaired Functioning Tool (LIFE-RIFT):19 We 
defined full remission as HRSD score below 8 and LIFE-RIFT score below 13; and partial remission as 
HRSD score below 15 and LIFE-RIFT score below 13 points.
We measured suicidal ideation using the assessor-rated Modified Scale for Suicidal Ideation (MSSI);20 
total scores less than 9 show low ideation. 
After three months, and the other four points, we collected data on potential mediating variables:
Acceptance & Action Questionnaire-II (AAQ-II)21 measuring psychological inflexibility. 
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Emotional Approach Coping (EAC) scale22 measuring Emotional Processing and Emotional 
Expression. 
Patient Health Questionnaire-9 (PHQ-9)23 measuring depression severity.
The 3-item Social Support Questionnaire (SSQ-3)24 measuring responders’ satisfaction with support.
At baseline we also recorded potential moderating variables, notably age, sex and marital status. 
Sample size 
Two pilot studies of an earlier but similar version of RO DBT for refractory depression showed effect 
sizes at end of treatment of 0.8511 and 0.71.10  We aimed to recruit enough analysable participants to 
yield 80% power to detect as statistically significant at the 5% level a standardised difference of 0.4 
between RO DBT and TAU. We judged that clinicians and the UK National Institute of Health and 
Care Excellence (NICE) would consider this, equivalent to a mean difference of two points on the 
HRSD, to be ‘clinically important’. 
If there were no correlation between patients with the same therapist, a sample of 200 analysable 
participants would detect such a difference. As we aimed to collect analysable data from at least 
83% of participants, we increased our target to 240. To focus on the mechanisms of RO DBT we 
randomised in the ratio 3:2 by allocating 144 ‘unclustered’ patients to RO DBT and 96 to TAU. 
However RO DBT participants cluster by therapist. To allow for an intra-therapist correlation 
coefficient of 0.025 between HRSD scores, and an average cluster size of 11 participants for each of 
the expected 16 therapists, we increased the RO DBT sample size to 180, yielding the same statistical 
power as 144 unclustered participants. Thus we aimed to randomise 276 patients – 180 to RO DBT 
and 96 to TAU. We planned no interim analysis or stopping rule apart from that imposed by funding.
Randomisation and masking
Once we had confirmed eligibility and received informed consent through the form approved by 
Hampshire Research Ethics Committee, we randomised participants between treatments. We used 
three stratifying variables to ensure balance between groups – early or late onset of depression, 
HRSD score above or below 25, and presence or absence of PD. Within the RO DBT group, we 
randomised participants between available therapists so as to use as many as feasible of the 
treatment slots at each centre. To minimise risk of subversion, the Swansea Trials Unit used dynamic 
randomisation to make these allocations stochastically rather than deterministically.25 They emailed 
the resulting allocations to the Trial Manager for dissemination to participants and study therapists, 
but not assessors.
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To keep assessors blind to treatment allocations they: conducted assessments away from treatment 
centres; asked participants not to reveal their allocations during assessments; and avoided clinical 
notes after initial assessment. If an allocation were revealed, we reblinded by using another assessor 
for later assessments. If the allocation were revealed during assessment, we used the unblinded 
ratings; this happened 17 times at month seven, 12 times at month 12, but not at all at month 18. 
Assessor Reliability13
A clinical psychologist experienced in administering SCID and HSRD in clinical trials (HO’M) trained 
assessors to administer all these outcome measures. The minimum requirement for RefraMED 
assessors was a degree in Psychology or closely related field. In reality all assessors had 
postgraduate qualifications, mainly MSc, DClinPsy or PhD. We discussed queries at weekly consensus 
meetings. We assessed inter-rater reliability for the HRSD at 9-month intervals across nine assessors. 
We analysed the reliability of individual items, more rigorous than analysing total scores. Across all 
measurements Krippendorff’s alpha was 0.89 (95% CI from 0.86 to 0.92), implying “very good” to 
“near perfect” inter-rater reliability.26
Statistical methods
To create a dataset for analysis, we linked study datasets by randomisation codes. We validated this 
database by comparing information across sources, and by entering data twice. We scored all 
measures according to their published rules for imputing missing data. 
We used the lmerTest package for the statistical language R to fit linear mixed effects models to 
primary and secondary outcomes over the 18 months from baseline.27 Covariates included 
treatment allocated, treatment centre, baseline HRSD score, early or late onset of depression, and 
presence or absence of PD at baseline. We used a 3-level mixed-effects model to account for 
clustering of data by patient and therapist, avoiding the assumption that all therapists are equally 
effective. These mixed models are efficient and unbiased when data are missing at random. Without 
suitable auxiliary data we did not impute missing responses, for example by multiple imputation. 
However, when fewer than 10% of items were missing in a given scale, we imputed them by linear 
regression using the other scale items as covariates. For each outcome we estimated the main 
effects of treatment allocation and time, and the interaction between them; and compared groups 
at months 7, 12 and 18 by treatment allocated. 
In assessing remission from depression, we used Button’s criterion of a 17.5% change in HRSD scores 
from baseline.28 We refitted our mixed models using the Bayesian software Stan, and the associated 
R package ‘brms’.29 We assessed heterogeneity in therapist performance by intra-therapist 
correlation coefficients (ICCs), and simulated prognoses for future patients on RO DBT. Analyses post 
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hoc estimated posterior odds ratios30 for hypotheses of interest. We derived remission rates from 
predictions based on continuous outcomes, so did not need to test for differences in these rates 
directly. 
Serious adverse events
Our report to NIHR describes how we monitored Serious Adverse Events (SAEs).13 The Chief 
Investigator reviewed these immediately, and reported them to the Data Monitoring & Ethics 
Committee (DMEC) every year, or immediately if there was Suspicion of an Unexpected Serious 
Adverse Reaction (SUSAR). 
Ethical approval and conduct
Before recruiting patients we gained approval from the Hampshire Research Ethics Committee 
(National Research Ethics Service [NRES] reference 11/SC/0146) and the Research Governance 
Department of the University of Southampton, the Sponsor of this trial. We asked trial participants 
for consent on three occasions: before telephone screening; before baseline assessment; and before 
randomisation.
Patient and public inclusion
The NIHR Mental Health Research Network and ‘Involve’, the national advisory group on public 
engagement, helped us recruit service users – two to the Trial Steering Committee (TSC) and two to 
the Trial Management Group (TMG). These users contributed to patient information leaflets, 
managing the trial, and disseminating findings.
Data availability 
All non-confidential data and syntax for analyses reported here are available in the online data 
supplement with doi: 10.5281/zenodo.1442883. 
Role of the funding source
The Efficacy & Mechanism Evaluation (EME) Programme, funded by the MRC and administered by 
the National Institute for Health Research (NIHR), funded this trial by grant 09/150/12. NIHR 
monitored the trial and appointed the independent members of the TSC and DMEC. The grant 
holders were responsible for: study design; collecting, analysing, and interpreting data; writing this 
paper; and submitting for publication.
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Results
 Insert Figure 1 here
Recruitment
Figure 1 shows the flow of participants through the RefraMED trial: we randomised 250 eligible 
patients, 162 (65%) to RO DBT and 88 to control. Recruitment started in Dorset in March 2012 with an 
internal pilot; started in Hampshire and North Wales in September 2012; and continued until April 
2015. Of the 250 randomised participants, 170 (68%) came from secondary care, 55 (22%) from 
primary care database searches, 19 (8%) from self-referral and six (2%) from other sources, notably 
private practitioners.13 
Of 162 participants allocated to RO DBT plus TAU, 34 (21%) withdrew, including ten who attended no 
sessions, four who attended only one or two sessions; and ten prevented from continuing by work or 
family commitments. If participants did not attend a follow-up appointment after 7 or 12 months, we 
asked them to attend the next scheduled follow-up. For example, six of the fourteen RO DBT 
participants who did not attend their appointment after 7 months did attend their appointment after 
12 months. This explains why we analysed more participants after 12 months (130) than after 7 (124).
Of 88 control participants, 22 (25%) withdrew, including nine because they resented allocation to 
TAU. Only one of those withdrawing from treatment agreed to stay in the study for follow-up 
interviews. So the proportion of participants analysed at month 12 did not differ significantly between 
groups (Chi squared = 0.71 with one degree of freedom; p = 0.40).  
Baseline data – demographic and clinical
Of the full sample of 250, 164 (64%) were female; 138 (55%) were aged between 35 and 55; 232 (97% 
of 238 responders) were ‘white’; 106 (42%) reported being in a stable relationship; and 82 (34% of 
241 responders) had a University qualification. Ninety-two participants (37%) reported a first 
depressive episode before the age of 16; 179 (84% of 213 responders) were chronically rather than 
recurrently depressed; and 191 (82% of 234 responders) had previously received psychotherapy. Our 
sample also showed high comorbidity: 217 (87%) with at least one axis-I disorder, and 197 (79%) with 
at least one axis-II disorder; only nine (4%) had no psychiatric comorbidity.13 Our report also confirms 
that our adaptive randomisation procedure was effective in balancing the characteristics of 
participants across groups; treatment centres were also generally comparable in participants’ 
characteristics.13
Delivery of therapy
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Of 23 therapists we trained, one did not provide therapy within RefraMED. The number of 
participants seen by the other therapists ranged from one to 17, with a mean of 6.9 and median of 7. 
The mean number of individual sessions attended by participants was 22.9 (SD 6.9; 79% of the 29 
planned); while the mean number of group sessions attended was 19.9 (SD 7.6; 74% of the 27 
planned).
Treatment fidelity
We rated 273 (9%) tapes; and adjudged 221 (81%) of these adherent with a score of 4.0 or more. 
Krippendorff’s alpha was 0.89 (95% CI from 0.86 to 0.92), suggesting “very good” consistency between 
those rating fidelity.
Primary outcome: depressive symptoms measured by HRSD
Table 1 and Figure 2 compare HRSD and the five secondary continuous outcome variables between 
groups across all follow-ups. 
 INSERT Table 1 and Figure 2
Depressive symptoms in both groups improved continuously from baseline to 18 months. By the end 
of therapy at seven months, RO DBT had substantially r duced depressive symptoms relative to TAU 
by 5.40 HRSD points (95% CI 0.94 to 9.85; effect size = 1.03; p = 0.02). RO DBT participants maintained 
their improvement in depressive symptoms at 12 and 18 months, but control participants improved 
more after 7 months, reducing the difference between-groups. The difference of 2.15 HRSD points at 
12 months exceeded our prior target of 2 points but was not statistically significant (95% CI -2.28 to 
6.58; effect size = 0.41; p = 0.29). At 18 months the difference fell to 1.69 HRSD points (95% CI -2.84 to 
6.22; effect size = 0.32; p = 0.42). Thus our planned contrasts revealed a statistically significant 
difference between RO DBT and TAU after seven months, but not after 12 or 18 months. In contrast 
Bayesian analysis post hoc provided evidence that RO DBT was superior to TAU across all follow-ups: 
the posterior odds ratio was: 46 at 7 months – suggesting “strong” evidence;30 and 5.5 and 4.7 at 12 
and 18 months respectively – suggesting “positive” evidence.30  Figure 3 displays the posterior 
probability that RO DBT achieved the range of effects on the x-axis. The likely causes of the trial’s 
reduced power was the combination of under-recruitment and unexpectedly large therapist 
heterogeneity, yielding an ICC of 0.14, much larger than the ICC of 0.025 postulated in our power 
analysis. The most and least effective therapists, judged by clinical outcomes of their participants, 
differed by 2.6 HRSD points, equivalent to a standardised effect size of 0.43.
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 INSERT Figure 3
Remission rates
Using primary criteria, full remission rates were low in both groups: 1%, 8% and 7% for RO DBT and 
0%, 0% and 1% in controls, at 7, 12 and 18 months respectively; and partial remission rates were 
higher for RO DBT – 23%, 26% and 33% at successive assessments – than in controls – 6%, 22% and 
24% at successive assessments. Using the criterion of ‘worthwhile’ change, namely 17.5% reduction in 
symptoms from baseline,28 remission rates were: 59%, 69% and 59% for RO DBT at 7, 12 and 18 
months; and 27%, 48% and 41% in controls. 
To help patients and clinicians interpret our findings, we simulated likely outcomes for new patients, 
estimating that, for every 100 new patients, 32 would achieve 17.5% improvement in symptom scores 
after 12 months by choosing RO DBT rather than TAU, while ten would deteriorate by the same 
criterion, and 58 would remain essentially unchanged.
Secondary continuous outcomes 
RO DBT participants achieved significant gains in psychological flexibility and emotional coping relative 
to controls throughout the trial (Table 1 and Figure 2). Mean AAQ scores, measuring psychological 
inflexibility decreased over time, especially after RO DBT; the effect size increased from 0.49 (medium) 
after seven months to 0.72 (large) after 12, and 0.79 after 18. EAC scores, measuring emotional 
coping, increased after RO DBT, but not after TAU; the effect size increased from 0.32 (small) after 
seven months to 0.76 (large) after 12 months and 0.64 (also large) after 18. 
However Table 1 shows no significant advantage for RO DBT in functional impairment, suicidal 
ideation or perceived social support. Mean MSSI suicidal ideation scores remained low throughout the 
trial for both groups; and although mean SSQ (perceived social support) scores increased after RO 
DBT, the difference between groups was never significant. 
Serious adverse events
We received reports of 32 serious adverse events (SAEs) – four from the 88 participants allocated to 
TAU and 28 from the 162 participants allocated to RO DBT;13 none of these led to withdrawal from the 
trial. In the RO DBT group, 21 participants experienced a single event; two experienced two events 
each; and one participant experienced three events. Thus 24 RO DBT participants experienced SAEs. 
We judged that all four events in the TAU group and 13 in the RO DBT group were “definitely not 
related” to the study intervention, for example a leg fracture and one death due to natural causes. We 
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judged that another eight were “unlikely to be related”, for example recurrent non-suicidal self-injury 
starting before the trial. Of the remaining eight SAEs, all from the intervention group, we judged that 
five were “possibly related” to RO DBT, including two overdoses, and three were “probably related”, 
including a prevented suicide attempt. Nevertheless we classed none of those eight serious adverse 
reactions (SARs) as “suspected unexpected” requiring immediate reporting to the Research Ethics 
Committee.
Thus all eight serious adverse reactions judged as potentially related to RO DBT occurred in the 
intervention group (Fisher’s Exact Test; one-tailed p = 0.004). However trial assessors saw control 
participants only at the three follow-up interviews, so that SAE reporting relied on their volunteering 
relevant information. In contrast trial therapists saw RO DBT participants twice a week, and they 
completed diary cards reporting on suicidal ideation and self-harm. We tried to ameliorate reporting 
bias by asking participants’ GPs to report any SAEs they encountered. However no one outside the 
RefraMED team reported an SAE: control participants reported all four SAEs either during assessment 
or to the trial office. In the RO DBT group therapists reported 23 (82%) SAEs, and participants reported 
only five. We believe the imbalance was due to these gross differences in reporting opportunities and 
encouragement from therapists to use those opportunities. 
As in both previous trials of RO DBT,10,11 there were no suicides in this trial. For all these reasons the 
Data Monitoring Committee saw “no reason to suspect RO DBT had adverse effects on patients”.
Discussion
Principal findings
In participants with refractory depression, Radically Open Dialectical Behaviour Therapy (RO DBT) was 
not statistically superior to treatment as usual (TAU) on the Hamilton Rating Scale for Depression 
(HRSD) at our primary endpoint of 12 months after randomisation, despite achieving the target 
moderate effect size of 0.40. However it was substantially better than TAU immediately after 
treatment, with an effect size of 1.03, much larger than reported by previous trials of psychotherapy 
for refractory depression.4. The later fall in effect size stems from rapid improvement during RO DBT, 
and initially-slow but accelerating improvement during TAU. Bayesian analysis post hoc generated 
“positive” evidence of the superiority of RO DBT over 18 months; and suggests that 22% (viz 32% less 
10%) more patients would experience “worthwhile change” at 12 months by choosing RO DBT over 
TAU. 
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Psychological outcomes
RO DBT aims to help individuals with rigid psychological and interpersonal styles learn flexibility. 
Reassuringly RO DBT participants reported significantly better psychological flexibility than the 
controls throughout the 18 months of follow up. RO DBT also aims to encourage appropriate 
expression of emotion to avoid isolation. Again RO DBT participants reported significantly better 
emotional processing throughout these 18 months. Both findings suggest that participants continue to 
use and improve their RO DBT skills. However there was no significant advantage for RO DBT in 
functional impairment, suicidal ideation or perceived social support. Throughout the trial suicidal 
ideation was low in both groups; though this decreased further over time in both groups, the 
difference was never significant. This finding was probably due to both groups continuing to receive 
treatment and support either from the trial or from the National Health Service. Though social 
support scores increased after RO DBT and decreased after TAU, the difference between groups was 
never significant. 
Strengths
RO DBT is the first treatment known to us to target deficits in social signalling as the main problem 
underlying overcontrolled emotional loneliness. We designed RefraMED as a hybrid between a Phase 
2 efficacy trial and a Phase 3 effectiveness trial. The former yielded strengths in: the consistency of 
both intervention and assessment; allocating therapists to patients at random rather than allocating 
difficult patients to the most skilled therapists.13 The latter yielded strengths in: minimising exclusion 
criteria thus including a wide range of patients with depression and maximising generalisability; 
enabling the treatment developer to train therapists rather than provide therapy; and facilitating cost-
effectiveness analysis. 13 
Limitations
Despite our best efforts to recruit 276 participants, and analyse 229 (83%) of them, we recruited only 
250 and analysed only 190 (76%); we also encountered unexpectedly large therapist heterogeneity. 
Despite achieving our target effect size at 12 months, the resulting loss of power meant our pre-
planned analyses did not achieve statistical significance beyond month 7. 
Interpretation
RefraMED was the first multi-centre trial of RO DBT. Though RO DBT greatly improved depressive 
symptoms by the end of treatment, our planned analyses were not statistically significant thereafter. 
Bayesian analysis post hoc suggests that RO DBT was superior to TAU throughout, but this effect was 
not clinically significant after month 7.
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RO DBT does not label depression as the primary problem. Instead it targets emotional overcontrol – a 
maladaptive personality style known to predict the development of chronic internalising disorders like 
refractory depression. Overcontrolled PDs, including obsessive-compulsive PD, are more common 
than undercontrolled PDs; and patients’ innate capacity to tolerate distress, delay gratification, and 
avoid public displays of emotion make their problems less noticeable, and them less likely to seek 
mental health treatment. Hence it is reassuring that RO DBT improved psychological flexibility and 
emotional processing over 18 months in a highly symptomatic population, most of whom suffer 
several mental health problems. 
Implications for future research
Given the recurring nature of depression, and RO DBT’s aim of changing maladaptive personality, 
future studies should investigate long-term differences between RO DBT and other treatments. The 
high proportion of comorbid disorders in RefraMED (96%), and the evidence that patients with 
complex mental disorders do not benefit much from short-term psychotherapy,31 support this 
proposal. RO DBT’s trans-diagnostic approach justifies testing RO DBT across a range of conditions, 
including overcontrolled personality disorders (Clusters A and C), anxiety disorders, and eating 
disorders.32
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CONSORT 2010 checklist of information to include when reporting a randomised trial*
Section/Topic
Item 
No Checklist item
Reported 
on page No
Title and abstract
1a Identification as a randomised trial in the title P1
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see 
CONSORT for abstracts)
P2
Introduction
2a Scientific background and explanation of rationale P3Background and 
objectives
2b Specific objectives or hypotheses P3
Methods
3a Description of trial design (such as parallel, factorial) including allocation ratio Pp4 & 6Trial design
3b Important changes to methods after trial commencement (such as eligibility criteria), with 
reasons
P4
4a Eligibility criteria for participants P4Participants
4b Settings and locations where the data were collected P4
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and 
when they were actually administered
Pp4 & 5
6a Completely defined pre-specified primary and secondary outcome measures, including how 
and when they were assessed
Pp5 & 6Outcomes
6b Any changes to trial outcomes after the trial commenced, with reasons Not 
applicable
7a How sample size was determined P6Sample size
7b When applicable, explanation of any interim analyses and stopping guidelines P6
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Randomisation:
8a Method used to generate the random allocation sequence P6 Sequence 
generation
8b Type of randomisation; details of any restriction (such as blocking and block size) P6 
 Allocation 
concealment 
mechanism
9 Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until 
interventions were assigned
P6 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions
P6
11a If done, who was blinded after assignment to interventions (for example, participants, care 
providers, those assessing outcomes) and how
P6Blinding
11b If relevant, description of the similarity of interventions Not 
applicable
12a Statistical methods used to compare groups for primary and secondary outcomes P7Statistical 
methods
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses P7
Results
13a For each group, the numbers of participants who were randomly assigned, received intended 
treatment, and were analysed for the primary outcome
P9, Fig 1Participant flow (a 
diagram is 
strongly 
recommended) 13b For each group, losses and exclusions after randomisation, together with reasons P9, Fig 1
14a Dates defining the periods of recruitment and follow-up P9Recruitment
14b Why the trial ended or was stopped Not 
applicable
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Description 
p9 – table 
can be added 
as 
supplemental 
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material if 
requested
Numbers 
analysed
16 For each group, number of participants (denominator) included in each analysis and whether 
the analysis was by original assigned groups
Fig 1 & p2 & 
p7
17a For each primary and secondary outcome, results for each group, and the estimated effect 
size and its precision (such as 95% confidence interval)
Pp10-11, 
Table 1, 
Figures 2 & 3
Outcomes and 
estimation
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended P11
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory
Not 
applicable
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Pp11 & 12
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity 
of analyses
P13
Generalisability 21 Generalisability (external validity, applicability) of the trial findings P13
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other 
relevant evidence
Pp12 & 13
Other information
Registration 23 Registration number and name of trial registry P1
Protocol 24 Where the full trial protocol can be accessed, if available Reference 11
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders P8
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If 
relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal 
interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-
statement.org.
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